Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic monitoring of oral disease-modifying drugs in multiple sclerosis
2021-003195-13Phase 4Completed
- Sponsor
- University Hospital Ostrava
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of teriflunomide, cladribine, dimethyl fumarate and fingolimod in multiple sclerosis (MS) (4 cohorts), sponsored by University Hospital Ostrava. Started Jun 2021; status: completed.
02
Drugs
teriflunomidecladribinedimethyl fumaratefingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-003195-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003195-13.